Electra Therapeutics raised $350 million in an upsized initial public offering to fund development of its precision immunology pipeline. The company’s lead candidate targets secondary hemophagocytic lymphohistiocytosis, a rare hyperinflammatory disorder with limited or no FDA-approved therapies. The financing also underscores how investors are continuing to reward clinical-stage franchise concepts that map to clear, unmet indications in immunology—particularly when biomarker and patient selection strategies are central to the drug’s development plan. Beyond Electra, the IPO activity reflects a broader biopharma capital market appetite for near-term clinical readouts in immune-driven diseases, where trial design and endpoints can translate into more binary regulatory paths. For the sector, the latest cash infusion increases the probability of faster operational execution across trials and manufacturing planning.